AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04670068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.B7-H3
Description: Two dose levels will be evaluated: Dose Level 1 (7.5x10\^7 cells/infusion), dose Level 2 (2x10\^8 cells/infusion). If dose limiting toxicities (DLTs) are observed per protocol, Dose Level -1 (3.75x10\^6 cells/infusion) will be evaluated.
Study NCT04670068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV for 3 consecutive days
Study NCT04670068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 IV for 3 consecutive days
Study NCT06064864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab-Dyyb
Description: Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30
Study NCT06064864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab-Dyyb
Description: Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30
Study NCT05319249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: NK cells will be given as a single intravenous infusion.
Study NCT05319249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib 1 MG [Talzenna]
Description: Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.
Study NCT05563428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: A free gingival graft will be carried out for recession treatment.
Study NCT05563428 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: The pouch technique with a connective tissue graft will be carried out for recession treatment.
Study NCT05375994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and adagrasib
Description: The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion
Study NCT04583579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMV inserter (DMV® MagicTouch™) with an open end
Description: This is a device used to help apply scleral lenses.
Study NCT04583579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMV inserter (DMV® MagicTouch™) with a closed end
Description: This is a device used to help apply scleral lenses.
Study NCT04583579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three fingers (Patient's Hand)
Description: This is a device used to help apply scleral lenses.
Study NCT04583579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O-ring (Hardware Store Product)
Description: This is a device used to help apply scleral lenses.
Study NCT04583579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tea light candle (Generic Deparment Store Product) with DMV inserter (DMV® MagicTouch™)
Description: This is a device used to help apply scleral lenses.
Study NCT05042635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab+Jueyin Granules
Description: Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times.
Study NCT05042635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab+Jueyin placebo Granules
Description: Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times.
Study NCT04953897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Study NCT04953897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASTX727
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Study NCT06156592 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac valve replacement surgery under high spinal anesthesia combined with light general anesthesia
Description: Before induction of general anesthesia, a high spinal anesthesia will be given using 37.5 mg of 0.75% heavy bupivacaine with 20 mcg fentanyl and 250 mcg epimorphine in sitting position at the lumbar intervertebral spaces between the L2-3 or L3-4 vertebrae. Patients will lie supine immediately afterwards, and sensory loss to ice will be performed every 15 seconds. Subsequently, the patient will be placed in 15-degree Trendelenburg (ensured by clinometer). Following general anesthesia will be induced and trachea will be intubated after 5 ml of 4% lignocaine spray on vocal cords and trachea. Hemodynamics will be aimed at MAP between 65-100 mmHg and heart rate between 50-100 beats /min by use of various inotropic, inodilators and vasoactive cardiac drugs based on anesthesiologists' clinical judgement.
Study NCT06129019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki application will be done
Study NCT04662931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizanlizumab
Description: Crizanlizumab 5.0 mg/kg i.v. initial dose on Week 1 Day 1, second dose on Week 3 Day 1. Subsequently, Day 1 of every 4 weeks until Week 51, in addition of standard of care.
Study NCT05799105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 40 milligrams
Description: Subjects will be randomized to treatment with either open-capsule or intact-capsule omeprazole to assess effect on ulcer healing times. If interim analysis illustrates significantly improved healing in the open-capsule group, the control (intact-capsule) arm will be allowed to cross-over to open-capsule and be followed until confirmed ulcer healing.
Study NCT05799105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 milligrams
Description: Subjects will be randomized to treatment with either open-capsule or intact-capsule omeprazole to assess effect on ulcer healing times. If interim analysis illustrates significantly improved healing in the open-capsule group, the control (intact-capsule) arm will be allowed to cross-over to open-capsule and be followed until confirmed ulcer healing.
Study NCT06545331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XB010
Description: IV administration of XB010
Study NCT06545331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV administration of Pembrolizumab
Study NCT06558422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin human
Description: Insulin infusion rate (IIR) will be determined either to maintain fasting serum insulin levels (MH protocol) or to reduce fasting serum insulin levels by approximately 50% toward euinsulinemia (RE protocol).
Study NCT06558422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate
Description: Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
Study NCT06558422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
Study NCT06558422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone, Human
Description: Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
Study NCT06558422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% D-glucose (aq)
Description: 20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
Study NCT06558422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [6,6-2H2] D-glucose
Description: Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
Study NCT06558422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [1-13C1] sodium acetate
Description: Stable isotope tracer administered to calculate de novo lipogenesis during pancreatic clamp.
Study NCT06558422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestle BOOST Plus
Description: Nutritional supplement will be administered to provide standardized mixed meals prior to the pancreatic clamp.
Study NCT06558422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KIND Bar
Description: Energy bar snack will be administered the evening before the pancreatic clamp.
Study NCT06558422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harvard Apparatus PHD ULTRA CP syringe pump
Description: Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
Study NCT06558422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Description: Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
Study NCT05239455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveos® Automated Blood Processing System
Description: This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.
Study NCT05780983 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: education and coaching on developing healthy nighttime sleep and daytime activity behaviors
Description: The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
Study NCT05683691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanquish System
Description: Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.
Study NCT05218993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A new dual-task measurement method with images
Description: Football players will perform Illinois t test with and without cognitive demand with images. These images will represent scenarios from football with some of the players in the scene are from his team and others from opposing team. The player will be asked to look at the image and say the number on the player in following scenarios; The player to whom he can pass the ball, The player who is most likely to intervene the ball, The player who can score the goal. In order to reduce the other possibilities, opposing team players will be positioned in a specific way to block all team-mates but one.
Study NCT05218993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A new dual-task measurement method with cards
Description: Football players will perform Illinois t test with and without cognitive demand with cards and balls. On the path of Illinois t test, there will be 3 football balls, 3-meters apart from each other, and there will be cards behind each, which can only be seen when the player about to hit the ball. This cards will vary in color (blue or red), which mean right or left. If the player sees red card, he will shoot the ball to the left side goal and if the player sees blue card, he will shoot the ball to the right side.
Study NCT06643663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic Micro-Surgery
Description: Surgery performed using ACM membrane and PRF plug in test group \& without membrane \& PRF in control group.
Study NCT06643663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic Micro-Surgery
Description: Surgery performed using ACM membrane and PRF plug in test group \& without membrane \& PRF in control group.
Study NCT06332807 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT002
Description: adeno-associated viral vector with human phenylalanine hydroxylase gene
Study NCT06405399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention. observation guide
Description: An observation checklist based on the Lasater Clinical Judgment Rubric (LCJR) was created and adapted to the simulated clinical experience in order to address the learning outcomes to be achieved by nursing students. This resulted in a list of forty items divided into four main groups: patient safety (8 items), communication and relationship with the patient (7 items), teamwork (7 items) and technical skills (18 items).
Study NCT05576077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBio-4101
Description: TBio-4101 is an autologous selected and expanded tumor infiltrating lymphocyte (TIL) product generated following ex vivo expansion of tumor reactive TIL population found in tumor harvest. After preparation with non-myeloablative lymphodepletion chemotherapy (cyclophosphamide and fludarabine) followed by low dose radiation,TBio-4101, and IL-2.
Study NCT05576077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered after TIL infusion and continue every 3-6 weeks for up to 2 years.
Study NCT05869149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel restaurant intervention to improve the food environment
Description: FRESH is a restaurant-based intervention in low-income neighborhoods in Baltimore, MD and the Washington, District of Columbia metro area that aims to improve the healthy prepared-food environment for consumers, informed by community members and other stakeholders. FRESH intervention components include food preparation, food access and procurement, and consumer nutrition environment. Activities will take place over 16 months, and include training restaurant chefs to use healthier cooking methods, partnering with restaurant suppliers to offer healthier ingredients, and offering point-of-purchase promotions to educate customers on the healthier promoted food options. Intervention staff will form strong relationships with restaurant owners and chefs via in-person visits at least twice a month. Data from the intervention trial will inform the development of a system dynamics simulation model that will allow stakeholders to test new policy ideas prior to implementation.
Study NCT06457347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra early (<24 hours) ruptured aneurysm clipping
Description: Aneurysms are clipped with open surgery in less than 24 hours after rupture to prevent early rebleeding.
Study NCT06457347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early (24-72 hours) ruptured aneurysm clipping
Description: Aneurysms are clipped with open surgery in 24 to 72 hours after rupture to prevent early rebleeding.
Study NCT04850495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04850495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT04850495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04850495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04850495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT04850495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study NCT06569706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nipple-Sparing Mastectomy, with immediate breast reconstruction
Description: It is an endoscopic approach for mastectomy using an axillary single port
Study NCT06509958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034
Study NCT06509958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrochloride Injection
Description: Ropivacaine Hydrochloride Injection
Study NCT05670925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Famitinib with/without nab-Palitaxel
Description: After enrollment confirmed, the regimen of Camrelizumab Combined with Famitinib will be conducted for 2 cycles (8 weeks). Patients of CR or PR after 2 cycles (8 weeks) will enter dual-therapy maintenance phase until disease progression and will be recorded as PFS-1α. Patients of PD after 2 cycles (8 weeks) will be recorded as PFS-1β. Patients of SD with 2 cycles of dual therapy wlii receive triple therapy regimen: Camrelizumab and Famitinib with nab-Paclitaxel.
Study NCT05539703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation to get a 2nd booster dose of COVID-19 vaccine
Description: Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
Study NCT05651178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human CD19-CD22 Targeted T Cells Injection
Description: Autologous genetically modified anti-CD19/CD22 CAR transduced T cells
Study NCT04904822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal bisection
Description: Uterine bisection vaginally by scalpel 24
Study NCT04904822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal bisection
Description: Uterine bisection by endokinfe
Study NCT06582784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy App
Description: Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study NCT05490264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-SNA002
Description: \[68Ga\]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography
Study NCT06582784 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 8 weeks with a final follow up at week 12.
Study NCT05248321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Powder
Description: 2g tranexamic acid powder will be given via the endoscopy directly to the peptic ulcer
Study NCT05667766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Release of Extended Pharmacogenomics Report at Week 1
Description: Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) by Week 1. Whole genome sequencing on a broader number of actionable variants as per international guidelines for cancer supportive care (identical to study arm) will be reported on at Week 13.
Study NCT05667766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Release of Extended Pharmacogenomics Report at Week 13
Description: Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) and reporting of a broader number of actionable pharmacogenomic variants as per international guidelines for cancer supportive care reported on by Week 1.
Study NCT05667766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Release of Extended Pharmacogenomics Report at Week 13
Description: Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) and reporting of a broader number of actionable pharmacogenomic variants as per international guidelines for cancer supportive care reported on by Week 1.
Study NCT06446115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality Headset applied to the participants during chemotherapy session. Participants select their preferred virtual reality experience (i.e., nature videos, meditations, interactive applications, etc). Virtual reality (VR) by definition, is a simulated experience consisting of an experiential environment created by hardware and software technology capable of provoking sensations of real experiences. It can be further divided into 1) immersive; 2) semi-immersive; and 3) non-immersive. Immersive VR employs head-mounted display (HMD) system technology to separate users from their surroundings and engage in real-time with a three-dimensional environment generated by a computer.
Study NCT06446115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preferred activity
Description: Participants will engage in a preferred activity such as reading, watching television, coloring, etc. during chemotherapy.
Study NCT06446115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants will be administered multiple pre and post intervention questionnaires including NCCN Distress thermometer, GAD-7 and CCVA.